Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes

Area of Science:

• Biotechnology
• Pharmacology
• Genetics

Background:

• Nucleic acid drugs represent a novel class of therapeutics with potential for treating various diseases.
• They offer unique advantages over traditional small molecules and biologics, enabling targeting of previously undruggable targets.
• Diseases targeted include cancers, viral infections, and genetic disorders.

Purpose of the Study:

• To review the advantages, classification, and clinical status of nucleic acid therapeutics.
• To highlight the challenges and recent advancements in nucleic acid drug delivery.
• To discuss the potential role of exosomes in overcoming delivery hurdles.

Main Methods:

• Literature review of nucleic acid therapeutics.
• Analysis of clinical status and product launches.
• Examination of advanced delivery platforms, including lipid nanoparticles and ligand conjugation.
• Discussion of exosome-based delivery systems.

Main Results:

• Over 10 nucleic acid drug products have been launched, with many more in clinical trials.
• Key challenges remain, primarily concerning the efficient delivery of nucleic acids to target sites.
• Lipid nanoparticles and ligand conjugation are current advanced delivery strategies.
• Exosomes show promise as a future delivery platform for nucleic acid drugs.

Conclusions:

• Nucleic acid therapeutics hold significant promise for treating a wide range of diseases.
• Efficient delivery remains a critical hurdle for widespread clinical application.
• Ongoing advancements in delivery technologies, particularly lipid nanoparticles and exosomes, are paving the way for broader therapeutic use.